Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 161Lymphoid 121Other hematologic neoplasm 73Myeloid 16Genitourinary 12Classical hematology 7Dermatologic 5Sarcoma 3Gastrointestinal 3Head & Neck 2Endocrine 2CNS 2Tumor-Agnostic 1Thoracic 1NET 1Gynecologic 1

Conditions

Recurrence 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 333Pemetrexed 274Cisplatin 226Paclitaxel 193pembrolizumab 177Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Bevacizumab 112Nivolumab 111Radiotherapy 84Etoposide 68durvalumab 61atezolizumab 57Ipilimumab 51Radiosurgery 49osimertinib 41130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lenalidomide × Thoracic × Clear all
NCT02963610 2021-12-30

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
3 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡